MCM
ENGN icon

MAI Capital Management’s enGene Therapeutics ENGN Stock Holding History

MAI Capital Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-776
Closed -$7.01K – 5059
2025
Q4 		$7.01K Hold
776
– – ﹤0.01% 2991
2025
Q3 		$5.3K Sell
776
-2,149
-73% -$9.8K ﹤0.01% 2998
2025
Q2 		$10.6K Sell
2,925
-75,142
-96% -$282K ﹤0.01% 2691
2025
Q1 		$350K Buy
78,067
+7,756
+11% +$48.2K ﹤0.01% 922
2024
Q4 		$468K Buy
+70,311
New +$546K ﹤0.01% 866

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

MAI Capital Management's ENGN Position: Q1 2026 in Review

MAI Capital Management sold out of enGene Therapeutics (ENGN) in Q1 2026, closing a stake of 776 shares — an estimated $7.01K sold.

MAI Capital Management first reported a position in ENGN in Q4 2024 and held it in 5 quarters. The position peaked at $468K in Q4 2024. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • MAI Capital Management reported no remaining enGene Therapeutics position as of Q1 2026 after selling out during the quarter.
  • MAI Capital Management sold 776 enGene Therapeutics shares in Q1 2026, an estimated $7.01K.
  • MAI Capital Management first reported a position in enGene Therapeutics in Q4 2024 and held it in 5 quarters.
  • MAI Capital Management's enGene Therapeutics position peaked at $468K in Q4 2024.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.